In seniors, hip fractures and resulting immobility result in high morbidity, and mortality of up to 30% in the first year. As yet, there is no therapy available to address the problem of impaired regeneration and mobility, and the consequences (including high mortality) after hip fracture surgery. Hipgen is a multicenter phase III trial which aims to bring allogenic placental cell therapy with PLX-PAD cells to market approval. As the first regenerative therapy for improving recovery following a surgically treated injury, the new therapy could potentially improve patients’ quality of life while also saving hospitalization and rehabilitation costs.
In a succinct three-part video interview, Professor Tobias Winkler, project coordinator of the Hipgen project, discusses the background and aims of the innovative project. He explains:
- The previous work Hipgen is based on and what the Phase I /II trials showed
- The core goals of the study
- How the new therapy could improve patient outcomes and quality of life
The HIPGEN project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779293.